Basilea Pharmaceutica Ltd

Basilea Pharmaceutica Ltd. announces that the U.S. FDA sets Anti-Infective Drugs Advisory Committee meeting on NDA for the investigational antifungal isavuconazole

Basel, Switzerland, 24-11-2014 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA)…

9 years ago

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data…

11 years ago

Basilea Pharmaceutica Ltd awarded USD 89M contract by U.S. Department of Health and Human Services division BARDA for the development of its novel antibiotic BAL30072

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA…

11 years ago